Inozyme Pharma Statistics

Total Valuation

Inozyme Pharma has a market cap or net worth of $80.30 million. The enterprise value is $13.44 million.

Market Cap	80.30M
Enterprise Value	13.44M

Important Dates

The next estimated earnings date is Tuesday, May 20, 2025, before market open.

Earnings Date	May 20, 2025
Ex-Dividend Date	n/a

Share Statistics

Inozyme Pharma has 64.24 million shares outstanding. The number of shares has increased by 21.17% in one year.

Current Share Class	64.24M
Shares Outstanding	64.24M
Shares Change (YoY)	+21.17%
Shares Change (QoQ)	+1.53%
Owned by Insiders (%)	0.54%
Owned by Institutions (%)	47.14%
Float	35.84M

Valuation Ratios

PE Ratio	n/a
Forward PE	n/a
PS Ratio	n/a
Forward PS	n/a
PB Ratio	1.38
P/TBV Ratio	1.38
P/FCF Ratio	n/a
P/OCF Ratio	n/a
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

EV / Earnings	n/a
EV / Sales	n/a
EV / EBITDA	n/a
EV / EBIT	n/a
EV / FCF	n/a

Financial Position

The company has a current ratio of 3.56, with a Debt / Equity ratio of 0.81.

Current Ratio	3.56
Quick Ratio	3.35
Debt / Equity	0.81
Debt / EBITDA	n/a
Debt / FCF	n/a
Interest Coverage	-18.72

Financial Efficiency

Return on equity (ROE) is -102.90% and return on invested capital (ROIC) is -44.57%.

Return on Equity (ROE)	-102.90%
Return on Assets (ROA)	-40.13%
Return on Invested Capital (ROIC)	-44.57%
Return on Capital Employed (ROCE)	-116.52%
Revenue Per Employee	n/a
Profits Per Employee	-$1.52M
Employee Count	67
Asset Turnover	n/a
Inventory Turnover	n/a

Taxes

Income Tax	n/a
Effective Tax Rate	n/a

Stock Price Statistics

The stock price has decreased by -73.28% in the last 52 weeks. The beta is 1.34, so Inozyme Pharma's price volatility has been higher than the market average.

Beta (5Y)	1.34
52-Week Price Change	-73.28%
50-Day Moving Average	1.04
200-Day Moving Average	3.04
Relative Strength Index (RSI)	54.98
Average Volume (20 Days)	1,068,036

Short Selling Information

The latest short interest is 4.42 million, so 6.89% of the outstanding shares have been sold short.

Short Interest	4.42M
Short Previous Month	4.21M
Short % of Shares Out	6.89%
Short % of Float	12.34%
Short Ratio (days to cover)	9.37

Income Statement

Revenue	n/a
Gross Profit	n/a
Operating Income	-104.03M
Pretax Income	-88.56M
Net Income	-102.02M
EBITDA	-103.29M
EBIT	-104.03M
Earnings Per Share (EPS)	-$1.62

Full Income Statement

Balance Sheet

The company has $113.09 million in cash and $46.87 million in debt, giving a net cash position of $66.21 million or $1.03 per share.

Cash & Cash Equivalents	113.09M
Total Debt	46.87M
Net Cash	66.21M
Net Cash Per Share	$1.03
Equity (Book Value)	57.83M
Book Value Per Share	0.90
Working Capital	86.78M

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was -$91.91 million and capital expenditures -$62,000, giving a free cash flow of -$91.97 million.

Operating Cash Flow	-91.91M
Capital Expenditures	-62,000
Free Cash Flow	-91.97M
FCF Per Share	-$1.43

Full Cash Flow Statement

Margins

Gross Margin	n/a
Operating Margin	n/a
Pretax Margin	n/a
Profit Margin	n/a
EBITDA Margin	n/a
EBIT Margin	n/a
FCF Margin	n/a

Dividends & Yields

Inozyme Pharma does not appear to pay any dividends at this time.

Dividend Per Share	n/a
Dividend Yield	n/a
Dividend Growth (YoY)	n/a
Years of Dividend Growth	n/a
Payout Ratio	n/a
Buyback Yield	-21.17%
Shareholder Yield	-21.17%
Earnings Yield	-128.08%
FCF Yield	-115.46%

Analyst Forecast

The average price target for Inozyme Pharma is $17.22, which is 1,277.60% higher than the current price. The consensus rating is "Strong Buy".

Price Target	$17.22
Price Target Difference	1,277.60%
Analyst Consensus	Strong Buy
Analyst Count	9
Revenue Growth Forecast (5Y)	n/a
EPS Growth Forecast (5Y)	n/a

Stock Forecasts

Stock Splits

This stock does not have any record of stock splits.

Last Split Date	n/a
Split Type	n/a
Split Ratio	n/a

Scores

Altman Z-Score	n/a
Piotroski F-Score	2